ID Biomedical Corp

ID Biomedical Corporation develops proprietary subunit vaccine products, including those based on its Proteosome platform intranasal adjuvant/delivery technology. The Company is developing non-live, subunit vaccines for the prevention of a number of different diseases, such as influenza and group A streptococcus, as well as vaccines against biological warfare agents.